Administration of myelin basic protein synthetic peptides to multiple sclerosis patients.
A double blind Phase 1 clinical research project was conducted in vivo in multiple sclerosis (MS) patients to determine the effect of myelin basic protein (MBP) synthetic peptides on free (F) and bound (B) titers of anti-MBP in cerebrospinal fluid (CSF). Intrathecal administration of peptide MBP75-95, either as a single dose, or as repeated injections for periods up to 10 weeks, produced complete binding-neutralization of F anti-MBP with no change in B levels. A control peptide MBP35-58 had no effect on F and B anti-MBP levels. Intravenous administration of MBP75-95 resulted in significant decline of F and B CSF anti-MBP levels over a period of one month. Administration of MBP synthetic peptides to MS patients either intrathecally or intravenously did not have any adverse neurological effects and systemic complications did not occur. The MBP epitope for MS anti-MBP was further localized to an area between Pro85 and Pro96.
Warren
K G
KG
Department of Medicine (Neurology), University of Alberta, Edmonton, Canada.
Catz
I
I
D000328:Adult; D000368:Aged; D000937:Antigen-Antibody Reactions; D001323:Autoantibodies / Q000134:cerebrospinal fluid; D004311:Double-Blind Method; D004334:Drug Administration Schedule; D018604:Epitope Mapping; D005260:Female; D006801:Humans; D007275:Injections, Intravenous; D008297:Male; D008875:Middle Aged; D009103:Multiple Sclerosis / Q000134:cerebrospinal fluid / Q000188:drug therapy* / Q000276:immunology; D004676:Myelin Basic Protein / Q000138:chemical synthesis / Q000276:immunology / Q000627:therapeutic use*; D010455:Peptides / Q000138:chemical synthesis / Q000627:therapeutic use*
D001323:Autoantibodies; D004676:Myelin Basic Protein; D010455:Peptides